288 related articles for article (PubMed ID: 22930197)
1. Long-term efficacy and safety of arsenic trioxide for first-line treatment of elderly patients with newly diagnosed acute promyelocytic leukemia.
Zhang Y; Zhang Z; Li J; Li L; Han X; Han L; Hu L; Wang S; Zhao Y; Li X; Zhang Y; Fan S; Lv C; Li Y; Su Y; Zhao H; Zhang X; Zhou J
Cancer; 2013 Jan; 119(1):115-25. PubMed ID: 22930197
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia.
Ghavamzadeh A; Alimoghaddam K; Rostami S; Ghaffari SH; Jahani M; Iravani M; Mousavi SA; Bahar B; Jalili M
J Clin Oncol; 2011 Jul; 29(20):2753-7. PubMed ID: 21646615
[TBL] [Abstract][Full Text] [Related]
3. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data.
Mathews V; George B; Chendamarai E; Lakshmi KM; Desire S; Balasubramanian P; Viswabandya A; Thirugnanam R; Abraham A; Shaji RV; Srivastava A; Chandy M
J Clin Oncol; 2010 Aug; 28(24):3866-71. PubMed ID: 20644086
[TBL] [Abstract][Full Text] [Related]
4. Long-term prognosis of childhood acute promyelocytic leukaemia with arsenic trioxide administration in induction and consolidation chemotherapy phases: a single-centre experience.
Cheng Y; Zhang L; Wu J; Lu A; Wang B; Liu G
Eur J Haematol; 2013 Dec; 91(6):483-9. PubMed ID: 24033687
[TBL] [Abstract][Full Text] [Related]
5. Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience.
Lazo G; Kantarjian H; Estey E; Thomas D; O'Brien S; Cortes J
Cancer; 2003 May; 97(9):2218-24. PubMed ID: 12712474
[TBL] [Abstract][Full Text] [Related]
6. Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia.
Zhou J; Zhang Y; Li J; Li X; Hou J; Zhao Y; Liu X; Han X; Hu L; Wang S; Zhao Y; Zhang Y; Fan S; Lv C; Li L; Zhu L
Blood; 2010 Mar; 115(9):1697-702. PubMed ID: 20029047
[TBL] [Abstract][Full Text] [Related]
7. Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia.
Lengfelder E; Hofmann WK; Nowak D
Leukemia; 2012 Mar; 26(3):433-42. PubMed ID: 21904379
[TBL] [Abstract][Full Text] [Related]
8. Long-term remission after first-line single-agent treatment with arsenic trioxide of relapsed acute promyelocytic leukemia in an 8-year-old boy.
Ebinger M; Schwarze CP; Feuchtinger T; Scheel-Walter HG; Lang P; Hildenbrand S; Gessler P; Handgretinger R
Pediatr Hematol Oncol; 2011 May; 28(4):334-7. PubMed ID: 21345080
[TBL] [Abstract][Full Text] [Related]
9. Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial.
Zhu HH; Wu DP; Jin J; Li JY; Ma J; Wang JX; Jiang H; Chen SJ; Huang XJ
J Clin Oncol; 2013 Nov; 31(33):4215-21. PubMed ID: 24127444
[TBL] [Abstract][Full Text] [Related]
10. Long-term survival and prognostic study in acute promyelocytic leukemia treated with all-trans-retinoic acid, chemotherapy, and As2O3: an experience of 120 patients at a single institution.
Hu J; Shen ZX; Sun GL; Chen SJ; Wang ZY; Chen Z
Int J Hematol; 1999 Dec; 70(4):248-60. PubMed ID: 10643151
[TBL] [Abstract][Full Text] [Related]
11. Arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: a single center experience.
Mathews V; Balasubramanian P; Shaji RV; George B; Chandy M; Srivastava A
Am J Hematol; 2002 Aug; 70(4):292-9. PubMed ID: 12210810
[TBL] [Abstract][Full Text] [Related]
12. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.
Lo-Coco F; Avvisati G; Vignetti M; Thiede C; Orlando SM; Iacobelli S; Ferrara F; Fazi P; Cicconi L; Di Bona E; Specchia G; Sica S; Divona M; Levis A; Fiedler W; Cerqui E; Breccia M; Fioritoni G; Salih HR; Cazzola M; Melillo L; Carella AM; Brandts CH; Morra E; von Lilienfeld-Toal M; Hertenstein B; Wattad M; Lübbert M; Hänel M; Schmitz N; Link H; Kropp MG; Rambaldi A; La Nasa G; Luppi M; Ciceri F; Finizio O; Venditti A; Fabbiano F; Döhner K; Sauer M; Ganser A; Amadori S; Mandelli F; Döhner H; Ehninger G; Schlenk RF; Platzbecker U; ; ;
N Engl J Med; 2013 Jul; 369(2):111-21. PubMed ID: 23841729
[TBL] [Abstract][Full Text] [Related]
13. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.
Thirugnanam R; George B; Chendamarai E; Lakshmi KM; Balasubramanian P; Viswabandya A; Srivastava A; Chandy M; Mathews V
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1479-84. PubMed ID: 19822309
[TBL] [Abstract][Full Text] [Related]
14. Incorporation of arsenic trioxide in induction therapy improves survival of patients with newly diagnosed acute promyelocytic leukaemia.
Song X; Hu X; Lü S; Gao L; Chen L; Yang J; Zhang W; Wang J
Eur J Haematol; 2014 Jul; 93(1):54-62. PubMed ID: 24592821
[TBL] [Abstract][Full Text] [Related]
15. Arsenic trioxide as effective therapy for relapsed acute promyelocytic leukemia.
Mayorga J; Richardson-Hardin C; Dicke KA
Clin J Oncol Nurs; 2002; 6(6):341-6. PubMed ID: 12434466
[TBL] [Abstract][Full Text] [Related]
16. How to manage acute promyelocytic leukemia.
Mi JQ; Li JM; Shen ZX; Chen SJ; Chen Z
Leukemia; 2012 Aug; 26(8):1743-51. PubMed ID: 22422168
[TBL] [Abstract][Full Text] [Related]
17. Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring.
Ohnishi K; Yoshida H; Shigeno K; Nakamura S; Fujisawa S; Naito K; Shinjo K; Fujita Y; Matsui H; Sahara N; Takeshita A; Satoh H; Terada H; Ohno R
Leukemia; 2002 Apr; 16(4):617-22. PubMed ID: 11960341
[TBL] [Abstract][Full Text] [Related]
18. Use of all-trans retinoic acid in combination with arsenic trioxide for remission induction in patients with newly diagnosed acute promyelocytic leukemia and for consolidation/maintenance in CR patients.
Dai CW; Zhang GS; Shen JK; Zheng WL; Pei MF; Xu YX; Cao YX; Yi Y; Yang JJ; Peng HL; Zhong HY; Li RJ
Acta Haematol; 2009; 121(1):1-8. PubMed ID: 19246888
[TBL] [Abstract][Full Text] [Related]
19. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies.
Douer D; Tallman MS
J Clin Oncol; 2005 Apr; 23(10):2396-410. PubMed ID: 15800332
[TBL] [Abstract][Full Text] [Related]
20. Arsenic trioxide-based therapy is suitable for patients with psoriasis-associated acute promyelocytic leukemia - A retrospective clinical study.
Ge F; Zhang Y; Cao F; Li J; Hou J; Wang P; Li H; Xu M; Liu S; Li L; Li X; Wang S; Lv C; Su Y; Zhou J
Hematology; 2016 Jun; 21(5):287-94. PubMed ID: 26871996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
